|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02616 CSTONE PHARMA-B
Nominal 
2.820 -0.040 (-1.399%) Profitability Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| ROAA (%) | -5.970% | -22.254% | -46.174% | -63.641% | -36.375% |
| ROAE (%) | -22.227% | -81.053% | -108.997% | -92.280% | -44.922% |
| Return on Capital Employed (%) | -12.820% | -45.245% | -130.455% | -143.451% | -40.221% |
Margin Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Gross Profit Margin (%) | 58.976% | 65.603% | 57.831% | 56.166% | 76.760% |
| EBITDA Margin (%) | -9.553% | -69.444% | -178.521% | -781.641% | -118.310% |
| Pre-tax Profit Margin (%) | -22.398% | -79.172% | -187.525% | -787.837% | -117.536% |
| Net Profit Margin (%) | -22.398% | -79.172% | -187.525% | -787.837% | -117.536% |
Liquidity Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Current Ratio (X) | 1.598 X | 1.564 X | 1.317 X | 2.098 X | 4.913 X |
| Quick Ratio (X) | 1.179 X | 1.436 X | 1.294 X | 2.033 X | 4.913 X |
Leverage Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Total Liabilities / Total Assets(%) | 73.887% | 72.513% | 72.576% | 46.862% | 21.481% |
| Total Debt / Total Assets (%) | 25.546% | 21.868% | 17.473% | 7.669% | 2.229% |
| Net Debt / Total Assets (%) | -2.294% | -38.100% | -16.625% | -25.029% | -78.153% |
| Total Debt / Shareholders' Funds (%) | 97.829% | 79.559% | 63.715% | 14.432% | 2.838% |
| Long Term Debt / Shareholders' Funds (%) | 72.212% | 49.063% | 53.719% | 10.791% | 2.455% |
| Net Debt / Shareholders' Funds (%) | -8.784% | -138.612% | -60.623% | -47.102% | -99.534% |
| Net Cash / (Debt) ($) | 31.964M | 633.223M | 272.394M | 568.526M | 2.941B |
| Net Cash / (Debt) per share ($) | 0.025 | 0.493 | 0.227 | 0.479 | 2.505 |
| Total Debt / Capital Employed (%) | 50.034% | 44.778% | 41.375% | 13.014% | 2.762% |
| Interest Coverage Ratio (X) | N/A | N/A | N/A | N/A | N/A |
Efficiency Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Inventory Turnover (Day) | 431.447 Day | 149.864 Day | 75.119 Day | 209.652 Day | N/A |
| Receivables Turnover (Day) | 114.898 Day | 98.194 Day | 73.829 Day | 176.119 Day | N/A |
| Payables Turnover (Day) | 261.917 Day | 211.202 Day | 267.177 Day | 331.219 Day | 11.478 Day |
| Remarks: | Real time quote last updated: 30/04/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -91,207,000 |
| %Change | -75.164% |
| EPS / (LPS) | RMB -0.070 |
| NBV Per Share (¥) | RMB 0.283 |